Novel hyperactive transposons for genetic modification of induced pluripotent and adult stem cells: A nonviral paradigm for coaxed differentiation

Stem Cells

Volumn 28, Issue 10, 2010, Pages 1760-1771

  Belay, Eyayu ^a   Mátrai, Janka ^a   Acosta Sanchez, Abel ^a   Ma, Ling ^a   Quattrocelli, Mattia ^a   Mátés, Lajos ^c   Sancho Bru, Pau ^a   Geraerts, Martine ^a   Yan, Bing ^a   Vermeesch, Joris ^d   Rincón, Melvin Yesid ^a   Samara Kuko, Ermira ^a   Ivics, Zoltán ^c,e   Verfaillie, Catherine ^a   Sampaolesi, Maurilio ^a   Izsvák, Zsuzsanna ^c,e   Vandendriessche, Thierry ^a,b   Chuah, Marinee K L ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

iPS; Mesenchymal stem cell; Muscle; Myoblast; Sleeping beauty; Stem cell; Transposon

Indexed keywords

BLOOD CLOTTING FACTOR 9; TRANSCRIPTION FACTOR PAX3; TRANSPOSASE;

ADULT; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOGENETICS; DNA MODIFICATION; GENE EXPRESSION; GENE TRANSFER; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; KARYOTYPE; LIVER CELL; MESENCHYMAL STEM CELL; MOLECULAR EVOLUTION; MUSCLE CELL; NERVE CELL; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; STEM CELL; TRANSPOSON;

ADULT STEM CELLS; ANIMALS; CELL DIFFERENTIATION; CELL LINE; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MICE; MUSCLE CELLS; NEUROGLIA; NEURONS; PAIRED BOX TRANSCRIPTION FACTORS; RETROELEMENTS; TRANSPOSASES;

IPS;

EID: 78149309453     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.501     Document Type: Article

References (55)

1. Vandendriessche T, Ivics Z, Izsvak Z et al. Emerging potential of transposons for gene therapy and generation of induced pluripotent stem cells. Blood 2009;114:1461-1468.
2. Ivics Z, Li MA, Mates L et al. Transposon-mediated genome manipulation in vertebrates. Nat Methods 2009;6:415-422.
3. Ivics Z, Hackett PB, Plasterk RH et al. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 1997;91:501-510.
4. Hollis RP, Nightingale SJ, Wang X et al. Stable gene transfer to human CD34(+) hematopoietic cells using the Sleeping Beauty transposon. Exp Hematol 2006;34:1333-1343.
5. Huang X, Wilber AC, Bao L et al. Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system. Blood 2006;107:483-491.
6. Zayed H, Izsvak Z, Walisko O et al. Development of hyperactive sleeping beauty transposon vectors by mutational analysis. Mol Ther 2004;9:292-304.
7. Geurts AM, Yang Y, Clark KJ et al. Gene transfer into genomes of human cells by the sleeping beauty transposon system. Mol Ther 2003;8:108-117. (Pubitemid 36939302)
8. Mates L, Chuah MK, Belay E et al. Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet 2009;41:753-761.
9. Grabundzija I, Irgang M, Mates L et al. Comparative analysis of transposable element vector systems in human cells. Mol Ther 2010;18:1200-1209.
10. Xue X, Huang X, Nodland SE et al. Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system. Blood 2009;114:1319-1330.
11. Izsvak Z, Chuah MK, Vandendriessche T et al. Efficient stable gene transfer into human cells by the Sleeping Beauty transposon vectors. Methods 2009;49:287-297.
12. VandenDriessche T, Chuah MK.Moving gene therapy forward with mobile DNA. Hum Gene Ther 2009;20:1559-1561.
13. Takahashi K, Yamanaka S.Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-676.
14. Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-872.
15. Yu J, Vodyanik MA, Smuga-Otto K et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318:1917-1920.
16. Yu J, Hu K, Smuga-Otto K et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009;324:797-801.
17. Nakagawa M, Koyanagi M, Tanabe K et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 2008;26:101-106.
18. Okita K, Ichisaka T, Yamanaka S.Generation of germline-competent induced pluripotent stem cells. Nature 2007;448:313-317.
19. Park IH, Arora N, Huo H et al. Disease-specific induced pluripotent stem cells. Cell 2008;134:877-886.
20. Park IH, Zhao R, West JA et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008;451:141-146.
21. Maherali N, Hochedlinger K.Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell 2008;3:595-605.
22. Stadtfeld M, Nagaya M, Utikal J et al. Induced pluripotent stem cells generated without viral integration. Science 2008;322:945-949.
23. Yusa K, Rad R, Takeda J et al. Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon. Nature Methods 2009;6:363-369.
24. Chang CW, Lai YS, Pawlik KM et al. Polycistronic lentiviral vector for "hit and run" reprogramming of adult skin fibroblasts to induced pluripotent stem cells. Stem Cells 2009;27:1042-1049.
25. Kaji K, Norrby K, Paca A et al. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009;458:771-775.
26. Hockemeyer D, Soldner F, Beard C et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol 2009;27:851-857.
27. Zou J, Maeder ML, Mali P et al. Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell 2009;5:97-110.
28. Hanna J, Wernig M, Markoulaki S et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007;318:1920-1923.
29. Raya A, Rodriguez-Piza I, Guenechea G et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 2009;460:53-59.
30. Chin MH, Mason MJ, Xie W et al. Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell 2009;5:111-123.
31. Lowry WE, Quan WL.Roadblocks en route to the clinical application of induced pluripotent stem cells. J Cell Sci 2010;123:643-651.
32. Karumbayaram S, Novitch BG, Patterson M et al. Directed differentiation of human-induced pluripotent stem cells generates active motor neurons. Stem Cells 2009;27:806-811.
33. Yamanaka S.A fresh look at iPS cells. Cell 2009;137:13-17.
34. Sampaolesi M, Blot S, D'Antona G et al. Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 2006;444:574-579.
35. Trollet C, Athanasopoulos T, Popplewell L et al. Gene therapy for muscular dystrophy: Current progress and future prospects. Exp Opin Biol Ther 2009;9:849-866.
36. Barberi T, Bradbury M, Dincer Z et al. Derivation of engraftable skeletal myoblasts from human embryonic stem cells. Nat Med 2007;13:642-648.
37. Darabi R, Gehlbach K, Bachoo RM et al. Functional skeletal muscle regeneration from differentiating embryonic stem cells. Nat Med 2008;14:134-143.
38. Messina G, Sirabella D, Monteverde S et al. Skeletal muscle differentiation of embryonic mesoangioblasts requires pax3 activity. Stem Cells 2009;27:157-164.
39. Conti L, Pollard SM, Gorba T et al. Niche-independent symmetrical self-renewal of a mammalian tissue stem cell. Plos Biol 2005;3:e283.
40. Doss MX, Chen S, Winkler J et al. Transcriptomic and phenotypic analysis of murine embryonic stem cell derived BMP2+ lineage cells: An insight into mesodermal patterning. Genome Biol 2007;8:R184:1-28.
41. Liu G, Aronovich EL, Cui Z et al. Excision of Sleeping Beauty transposons: Parameters and applications to gene therapy. J Gene Med 2004;6:574-583.
42. Bell JB, Podetz-Pedersen KM, Aronovich EL et al. Preferential delivery of the Sleeping Beauty transposon system to livers of mice by hydrodynamic injection. Nat Prot 2007;2:3153-3165.
43. Chuah MK, Van Damme A, Zwinnen H et al. Long-term persistence of human bone marrow stromal cells transduced with factor VIII-retroviral vectors and transient production of therapeutic levels of human factor VIII in nonmyeloablated immunodeficient mice. Hum Gene Ther 2000;11:729-738.
44. Van Damme A, Thorrez L, Ma L et al. Efficient lentiviral transduction and improved engraftment of human bone marrow mesenchymal cells. Stem Cells 2006;24:896-907.
45. Thorrez L, Vandenburgh H, Callewaert N et al. Angiogenesis enhances factor IX delivery and persistence from retrievable human bioengineered muscle implants. Mol Ther 2006;14:442-451.
46. Gang EJ, Bosnakovski D, Simsek T et al. Pax3 activation promotes the differentiation of mesenchymal stem cells toward the myogenic lineage. Exp Cell Res 2008;314:1721-1733.
47. Dai Y, Roman M, Naviaux RK et al. Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo. Proc Natl Acad Sci USA 1992;89:10892-10895.
48. Yant SR, Wu X, Huang Y et al. High-resolution genome-wide mapping of transposon integration in mammals. Mol Cell Biol 2005;25:2085-2094.
49. Deichmann A, Hacein-Bey-Abina S, Schmidt M et al. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J Clin Invest 2007;117:2225-2232.
50. Walisko O, Schorn A, Rolfs F et al. Transcriptional activities of the Sleeping Beauty transposon and shielding its genetic cargo with insulators. Mol Ther 2008;16:359-369.
51. Modlich U, Navarro S, Zychlinski D et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther 2009;17:1919-1928.
52. Modlich U, Baum C.Preventing and exploiting the oncogenic potential of integrating gene vectors. J Clin Invest 2009;119:755-758.
53. Ehrhardt A, Engler JA, Xu H et al. Molecular analysis of chromosomal rearrangements in mammalian cells after phiC31-mediated integration. Hum Gene Ther 2006;17:1077-1094.
54. Montini E, Cesana D, Schmidt M et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006;24:687-696.
55. Montini E, Cesana D, Schmidt M et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 2009;119:964-975.